LEGN (Legend Biotech) Construction In Progress: $0 Mil (As of Mar. 2026)


LEGN Legend Biotech Corp LEGN
73 GF Score
Price $28.70
GF Value $98.55
Valuation Possible Value Trap
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Construction In Progress?

Legend Biotech LEGN +0.91% 73 Construction In Progress is $0 Mil as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $98.55 (Possible Value Trap). The stock has 2 warning signs investors should review.

Legend Biotech's quarterly construction in progress increased from Sep. 2025 ($0 Mil) to Dec. 2025 ($15 Mil) but then declined from Dec. 2025 ($15 Mil) to Mar. 2026 ($0 Mil).

Legend Biotech's annual construction in progress increased from Dec. 2023 ($3 Mil) to Dec. 2024 ($5 Mil) and increased from Dec. 2024 ($5 Mil) to Dec. 2025 ($15 Mil).

Legend Biotech Construction In Progress Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Construction In Progress Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial 43.54 15.10 3.49 4.80 14.70

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.00 0.00 14.70 0.00
LEGN
73GF Score
Legend Biotech Corp LEGN
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $0 Mil mean?
Legend Biotech (LEGN) has a Construction In Progress of $0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Construction In Progress too high?
Legend Biotech's current Construction In Progress is $0 Mil. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Construction In Progress compare to DNTH and XENE?
Legend Biotech's Construction In Progress of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Legend Biotech and its competitors. Legend Biotech's current Construction In Progress is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.55, compared to a current price of $28.70 — trading 70.9% below its estimated fair value. The current Construction In Progress is $0 Mil. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Construction In Progress is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $28.70 is trading 70.9% below its estimated GF Value™ of $98.55. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Construction In Progress: $0 Mil
  • GF Value™: $98.55 vs. price of $28.70 (70.9% below fair value)
  • GF Score™: 73/100 with 2 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score

Get the complete analysis for LEGN

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.70
Price
$98.55
GF Value